Overview

Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:
0

Participant gender:
Female

Summary

Polycystic ovary syndrome accounts for the vast majority of anovulatory symptoms and hyperandrogenism in women. The diagnosis of Polycystic ovary syndrome has life-long implications, with increased risk for infertility, metabolic syndrome, and type 2 diabetes mellitus, and possibly for cardiovascular disease and endometrial carcinoma. Polycystic ovary syndrome is diagnosed in adolescents with otherwise unexplained, persistent hyperandrogenic anovulatory symptoms that are inappropriate for age and stage of adolescence. It should be considered in any adolescent girl with a chief complaint of hirsutism, treatment-resistant acne, menstrual irregularity, acanthosis nigricans, and/or obesity

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Clomiphene
Letrozole
Metformin

Criteria

Inclusion Criteria:

- polycystic ovaries patients who had failed to become pregnant after 3 courses of 150
mg of clomiphene citrate (considered as clomiphene resistant),whereas the value of the
above mentioned investigation are normal.

Exclusion Criteria:

1. women with other causes of infertility as male factor,tubal factor,those with
endocrine disorders as thyroid dysfunction and hyperprolactinemia.

2. women who received hormonal treatment or ovulation induction drugs in the last 3
months before the study.

3. women with history of liver,kidney or cardiovascular disease.